மரியஸ் ஒளேஜ்ணிக்ஜக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மரியஸ் ஒளேஜ்ணிக்ஜக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மரியஸ் ஒளேஜ்ணிக்ஜக் Today - Breaking & Trending Today

WPD Pharmaceuticals Provides Update on Audited Financial Statements


Share:
VANCOUVER, British Columbia, May 14, 2021 (GLOBE NEWSWIRE)
WPD Pharmaceuticals Inc. (the Company ) (CSE:WBIO) (FSE: 8SV1), provides this update on the status of the audit of its consolidated annual financial statements for the year ended December 31, 2020 (the
2020 Financial Statements ), the management discussion and analysis and the related officer certifications. As previously announced, the British Columbia Securities Commission issued a management cease trade order on May 4, 2021 because the Company was unable to timely file the 2020 Financial Statements, and the Company is filing this status update in accordance with National Policy 12-203,
Management Cease Trade Orders, which requires bi-weekly updates by way of news releases. ....

United Kingdom , British Columbia , Mariusz Olejniczak , Moleculin Biotech Inc , Neither The Canadian Securities Exchange , British Columbia Securities Commission , Investment Industry Regulatory Organization Of Canada , Pharmaceuticals Inc , Wake Forest University Health Sciences , Wake Forest University , National Policy , Management Cease Trade Orders , Moleculin Biotech , Canadian Securities Exchange , Investment Industry Regulatory Organization , ஒன்றுபட்டது கிஂக்டம் , பிரிட்டிஷ் கொலம்பியா , மரியஸ் ஒளேஜ்ணிக்ஜக் , இல்லை தி கனடியன் பத்திரங்கள் பரிமாற்றம் , பிரிட்டிஷ் கொலம்பியா பத்திரங்கள் தரகு , முதலீடு தொழில் ஒழுங்குமுறை ஆர்கநைஸேஶந் ஆஃப் கனடா , மருந்துகள் இன்க் , எழுந்திரு காடு பல்கலைக்கழகம் ஆரோக்கியம் அறிவியல் , எழுந்திரு காடு பல்கலைக்கழகம் , தேசிய பாலிஸீ , மேலாண்மை நிறுத்து வர்த்தகம் ஆர்டர்ஸ் ,

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate


WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “
Company” or “
WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of $6,730,036 (20,394,049.68 PLN) from the Polish National Center for Research and Development (“
NCRD”), for the development of Annamycin, the Company’s drug candidate used in the treatment of Acute Myeloid Leukemia (“
AML”).
Annamycin is a “next generation” anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin. The project entitled: “A novel approach to the therapy of acute myeloid leukemia (AML)” will be co-financed by the European Union, from the European Regional Development Fund, under the Smart Growth Operational Program 2014-2020. The funds will be used on the continued ....

New York , United States , United Kingdom , British Columbia , Mariusz Olejniczak , Thomas Renaud , European Regional Development Fund , National Center , Moleculin Biotech Inc , Investment Decisions , Wake Forest University Health Sciences , Smart Growth Operational Program , Neither The Canadian Securities Exchange , European Union , Investment Industry Regulatory Organization Of Canada , Pharmaceuticals Inc , Wake Forest University , Polish National Center , Acute Myeloid Leukemia , Moleculin Biotech , Canadian Securities Exchange , Investment Industry Regulatory Organization , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பிரிட்டிஷ் கொலம்பியா ,

WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements

WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas


Share:
WPD Pharmaceuticals Inc. (CSE:WBIO)(FSE: 8SV1) (the
Company or
WPD ) a clinical-stage pharmaceutical company, is pleased to announce that it will attend the 10
th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021.
During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: New approach to glioblastoma treatment addressing the critical unmet medical need , granted by National Research and Development Center (
NRDC ) and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020. ....

United States , New York , United Kingdom , British Columbia , Mariusz Olejniczak , Thomas Renaud , Moleculin Biotech Inc , Society Of Pediatric Oncology , National Research , Smart Growth Operational Program , Neither The Canadian Securities Exchange , European Union , Pharmaceuticals Inc , Wake Forest University , Investment Decisions , University Of Texas Md Anderson Cancer Center , During The Congress , Development Center , Wake Forest University Health Sciences , Reata Pharmaceuticals Inc , Strikepoint Media , Investment Industry Regulatory Organization Of Canada , Annual Congress , Polish Society , Pediatric Oncology , Clinical Trial Protocol ,